Psoriatic arthritis Trials in Duncansville, United States
Conditions / Psoriatic arthritis / Duncansville, United States
Clinical trials for Psoriatic arthritis investigate a range of treatment strategies and patient populations.
45 total trials for this combination
Showing top 10 of 45 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02538341 | Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) | COMPLETED | PHASE2 |
| NCT02029495 | Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis | TERMINATED | PHASE3 |
| NCT06588296 | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03675308 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00643526 | A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector | COMPLETED | EARLY_PHASE1 |
| NCT07148414 | A Study of SPY072 in Rheumatic Disease | RECRUITING | — |
| NCT04908189 | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02349295 | A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis | COMPLETED | PHASE3 |
| NCT03104400 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | COMPLETED | PHASE3 |
| NCT03104374 | A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug | COMPLETED | PHASE3 |